18-Nov-2026 07:59:58

LUPINGeneral news

Nomura on Lupin : Buy, TP Rs 2780

US sales decline priced in Cyclical weakness makes risk-reward favorable for next 1-2 years See upside risk to management's FY27 US sales guidance of $1.1-1.2bn, as erosion in gJynarque could be slower than anticipated (estimate is $1.25bn) Expect stock to find support from: 1) sustained above-market growth in domestic formulations, driven by chronic therapies; 2) a strong balance sheet (net cash of INR82bn in FY28F) that can be deployed for tuck-in acquisitions, leveraging the company's existing branded generics, complex generics and specialty platforms 3) visibility on complex generic launches in respiratory and biosimilars in FY30F and beyond Look forward to Co's ANDA filings on Respimat and Ellipta devices and key biosimilars in the next 6-9 months Co has successfully developed and gained approval for complex generic products, resulting in relatively higher sales per product in US.

LUPIN LIMITED

← Back to feed